{"denoms":[{"counts":[{"groupId":"BG000","value":"533"},{"groupId":"BG001","value":"536"},{"groupId":"BG002","value":"1069"}],"units":"Participants"}],"groups":[{"description":"Participants received pembrolizumab, 200 mg intravenous (IV) infusion, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m\\^2, IV infusion Q3W, Day 1 and Day 8 of each 3-week cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m\\^2 IV infusion, Q3W, Day 1 and Day 8 of each 3-week cycle for up to 8 cycles. Eligible participants who stopped the initial course of pembrolizumab with Stable Disease (SD) or better but progressed after discontinuation initiated a second course of pembrolizumab 200mg IV Q3W, Day 1 of each 3-week cycle for up to 17 cycles. Treatment with Gemcitabine could have been stopped at any time in first or second course due to toxicity or disease progression.","id":"BG000","title":"Arm A: Pembrolizumab + Chemotherapy"},{"description":"Participants received Placebo to Pembrolizumab, 200 mg IV infusion, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m\\^2 IV infusion, Q3W, Day 1 and Day 8 of each 3-week cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m\\^2 IV infusion, Q3W, Day 1 and Day 8 of each 3-week cycle for up to 8 cycles.","id":"BG001","title":"Arm B: Placebo + Chemotherapy"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.3","value":"63.3"},{"groupId":"BG001","spread":"11.0","value":"61.8"},{"groupId":"BG002","spread":"10.7","value":"62.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"253"},{"groupId":"BG001","value":"264"},{"groupId":"BG002","value":"517"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"280"},{"groupId":"BG001","value":"272"},{"groupId":"BG002","value":"552"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"111"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"433"},{"groupId":"BG001","value":"449"},{"groupId":"BG002","value":"882"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"76"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"245"},{"groupId":"BG001","value":"250"},{"groupId":"BG002","value":"495"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"14"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"256"},{"groupId":"BG001","value":"268"},{"groupId":"BG002","value":"524"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"7"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"25"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"242"},{"groupId":"BG001","value":"244"},{"groupId":"BG002","value":"486"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"291"},{"groupId":"BG001","value":"292"},{"groupId":"BG002","value":"583"}]}],"title":"Non-Asian"}],"description":"Randomization of participants was stratified by geographic region of the enrolling site (Asia or non-Asia).","paramType":"COUNT_OF_PARTICIPANTS","title":"Geographic Region","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"126"}]}],"title":"Locally Advanced"},{"categories":[{"measurements":[{"groupId":"BG000","value":"473"},{"groupId":"BG001","value":"470"},{"groupId":"BG002","value":"943"}]}],"title":"Metastatic"}],"description":"Randomization of participants was stratified by disease status as locally advanced or metastatic.","paramType":"COUNT_OF_PARTICIPANTS","title":"Disease Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"115"},{"groupId":"BG001","value":"118"},{"groupId":"BG002","value":"233"}]}],"title":"Gallbladder"},{"categories":[{"measurements":[{"groupId":"BG000","value":"320"},{"groupId":"BG001","value":"313"},{"groupId":"BG002","value":"633"}]}],"title":"Intrahepatic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"98"},{"groupId":"BG001","value":"105"},{"groupId":"BG002","value":"203"}]}],"title":"Extrahepatic"}],"description":"Randomization of participants was stratified by location of tumor as gallbladder or intrahepatic or extrahepatic bile duct cancers.","paramType":"COUNT_OF_PARTICIPANTS","title":"Site of Origin","unitOfMeasure":"Participants"}]}